Syngene Intl Peer Comparison

NSE: SYNGENE | BSE: 539268

₹372.50

₹-3.95 (-1.05%)

As on 22-Oct-2026 15:53IST

Market cap

₹15,021 Cr

Revenue (TTM)

₹3,600 Cr

P/E Ratio

P/B Ratio

3.2

Div. Yield

0.3 %

Edit

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	15,021	30,272	25,775	26,345	23,515
Revenue (₹ Cr)	3,600	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	221.00	414.00	-371.81	387.35	288.22
Net Margin (%)	6.01	11.23	-3.93	26.01	14.79
RoE (%)	5.62	8.38	-3.85	25.18	29.77
Price to Earnings	67.97	74.02	--	68.21	81.59
Price-To-Book	3.17	6.01	3.22	15.27	17.52

Income Statement (₹ Cr)

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	3,600.20	3,564.00	9,205.28	1,461.80	1,935.80
Total Income	3,678.50	3,686.00	9,449.59	1,489.25	1,948.58
Total Expenditure	2,797.30	2,792.00	8,195.15	919.25	1,485.56
EBITDA	802.90	772.00	1,010.13	542.56	450.24
Depreciation	453.90	226.00	857.51	37.68	50.83
EBIT	349.00	546.00	152.62	504.88	399.41
Interest	46.80	217.00	342.73	3.77	40.84
Other Income	78.30	122.00	244.31	27.45	12.78
Exceptional Items	-90.10	12.00	-216.88	0.00	0.00
Profit before Tax	290.40	463.00	-162.68	528.56	371.35
Provision for Tax	69.40	49.00	209.13	141.21	83.14
Profit after Tax	221.00	414.00	-371.81	387.35	288.22

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	4,839.10	4,940.00	8,162.62	1,653.56	1,288.82
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	663.30	1,712.00	5,044.14	42.40	202.03
Current Liabilities	1,552.30	1,622.00	4,758.28	230.82	835.87
Total Liabilities	7,054.70	8,578.00	17,723.32	1,983.96	2,326.71

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	4,046.90	5,343.00	10,211.52	1,026.85	519.60
Current Assets	2,142.80	2,606.00	7,191.66	881.27	1,681.81
Total Assets	7,054.70	8,578.00	17,723.32	1,983.96	2,326.71
Total Debt*	9.40	2,125.00	5,495.48	26.49	259.37
Net Current Assets	590.50	984.00	2,433.38	650.46	845.94
Contingent Liabilities	536.50	768.26	95.72	17.25	19.09

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	915.20	390.00	1,652.60	292.17	205.05
Cash Flow from Investing Activities	-860.40	-241.00	-826.03	-265.94	-409.72
Cash from Financing Activities	-215.00	-54.00	-38.98	4.10	283.07
Net Cash Inflow / Outflow	-160.20	95.00	787.59	30.33	78.39

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	9.48	6.79	1.24	32.42	29.22
ROE (%)	5.62	8.38	-3.85	25.18	29.77
ROA (%)	3.19	4.94	-2.21	21.93	24.77
EBIT Margin (%)	9.69	15.32	1.66	34.54	20.63
Net Margin (%)	6.01	11.23	-3.93	26.01	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	-3.41	18.37	0.78	40.90	46.65
EBIT Growth (%)	-45.08	252.26	-70.53	124.50	62.13
Net Profit Growth (%)	-56.43	377.85	-1,383.43	104.15	89.49
EPS Growth (%)	-46.98	1,001.33	-484.84	42.32	78.60
Book Value Growth (%)	2.11	13.47	0.33	26.03	144.31

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	56.34	76.44	-81.31	66.92	82.01
Price / Book Value	3.21	6.05	3.18	14.98	17.88
Dividend Yield (%)	0.33	0.00	0.00	0.08	0.10
EV/EBITDA	17.33	41.35	29.29	47.27	53.13
Market Cap (₹ Cr)	15,723.10	19,071.62	18,108.89	20,944.75	12,753.19

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.00	0.31	0.53	0.02	0.11
Short term debt to equity ratio	0.00	0.09	0.09	0.02	0.05
Current Ratio	1.38	1.61	1.51	3.82	2.01
Quick Ratio	1.29	1.06	0.87	2.82	1.14
Interest Coverage	7.21	3.13	0.53	141.16	10.09

	Syngene Intl	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	14.13	16.50	23.44	24.80	26.28
Asset Turnover	0.52	0.43	0.55	0.83	1.66
Receivable days	50.33	58.75	78.20	88.98	40.13
Inventory Days	14.43	75.82	93.30	56.04	60.29
Payable days	17,487.50	186.21	226.14	99.95	232.47
Cash Conversion Cycle	-17,422.74	-51.64	-54.64	45.07	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.